MTB-targeted phage therapy

Phase 1

JJinling Hospital, China

MTB-targeted phage therapy is one of 8 therapeutic programs targeting Pouchitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

PouchitisNot yet recruiting

PouchitisPhase 1

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Pouchitis

#DrugCompanyPhaseTrials

Entyvio

Takeda

Approved

2 2

Tremfya

Johnson & Johnson

Approved

1 3

Cipro

Bayer

Approved

1 4

Victoza

Xifaxan

1 6

Flagyl

Monurol

MTB-targeted phage therapy

JJinling Hospital, China

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1Not yet recruiting

Pouchitis

NCT07878026

Clinical

Trials by Indication[1]

Pouchitis1 trial

A Single-center, Prospective, Single-arm Clinical Research Protocol for the Treatment of Pouchitis With Aeromonas sp. MTB Bacteriophage

Not yet recruiting·JJinling Hospital, China·Phase 1·NCT07878026·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MTB-targeted phage therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for MTB-targeted phage therapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Jinling Hospital, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: JJinling Hospital, China

MTB-targeted phage therapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Pouchitis1 trial

References

Drug Info

Quick Facts

Related News